Myeloproliferative Disorder, Chronic, with Eosinophilia (MPE)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Myeloproliferative Disorder, Chronic, with Eosinophilia

MalaCards integrated aliases for Myeloproliferative Disorder, Chronic, with Eosinophilia:

Name: Myeloproliferative Disorder, Chronic, with Eosinophilia 56 29 39 71
Myeloproliferative Disorder with Eosinophilia 56 12 13 15
Mpe 56 73
Chronic Myeloproliferative Disorder with Eosinophilia 12
Myeloproliferative Disorder Chronic with Eosinophilia 73
Chronic Myeloproliferative Disease, Unclassifiable 58
Undifferentiated Myeloproliferative Disease 58
Myeloproliferative Neoplasm, Unclassifiable 71
Eosinophils, Malignant Proliferation of 56
Malignant Proliferation of Eosinophils 73
Mpe; Emp 56
Cmpd-U 58
Emp 56



autosomal dominant (12p13)


myeloproliferative disorder, chronic, with eosinophilia:
Inheritance autosomal dominant inheritance


Orphanet: 58  
Rare haematological diseases

External Ids:

Disease Ontology 12 DOID:0111344
OMIM 56 131440
ICD10 via Orphanet 33 D47.1
Orphanet 58 ORPHA86830
MedGen 41 C1851585
SNOMED-CT via HPO 68 263681008 414794006 425333006
UMLS 71 C1333046 C1851585

Summaries for Myeloproliferative Disorder, Chronic, with Eosinophilia

Disease Ontology : 12 A myeloproliferative neoplasm characterized by chronic proliferation of myeloid cells and eosinophilia in the peripheral blood and bone marrow that has material basis in a fusion of ETV6 and PDGFRB formed by a translocation from chromosome 12 to chromosome 5q32.

MalaCards based summary : Myeloproliferative Disorder, Chronic, with Eosinophilia, also known as myeloproliferative disorder with eosinophilia, is related to hypereosinophilic syndrome and myeloproliferative neoplasm. An important gene associated with Myeloproliferative Disorder, Chronic, with Eosinophilia is PDGFRB (Platelet Derived Growth Factor Receptor Beta). The drugs Mercaptopurine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and myeloid, and related phenotypes are eosinophilia and myeloproliferative disorder

UniProtKB/Swiss-Prot : 73 Myeloproliferative disorder chronic with eosinophilia: A hematologic disorder characterized by malignant eosinophils proliferation.

More information from OMIM: 131440

Related Diseases for Myeloproliferative Disorder, Chronic, with Eosinophilia

Diseases related to Myeloproliferative Disorder, Chronic, with Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 hypereosinophilic syndrome 30.5 PDGFRB FIP1L1
2 myeloproliferative neoplasm 29.9 PDGFRB FIP1L1 ETV6
3 pdgfrb-associated chronic eosinophilic leukemia 11.5
4 extramedullary plasmacytoma 10.4
5 plasmacytoma 10.4
6 lung cancer susceptibility 3 10.3
7 myeloma, multiple 10.3
8 vascular disease 10.3
9 renal cell carcinoma, nonpapillary 10.2
10 hemopericardium 10.2
11 pericardial effusion 10.2
12 benign mesothelioma 10.2
13 pulmonary embolism 10.2
14 multiple sclerosis 10.0
15 thymoma, familial 10.0
16 leukemia, acute lymphoblastic 10.0
17 infective endocarditis 10.0
18 endocarditis 10.0
19 pneumoconiosis 10.0
20 asbestosis 10.0
21 anthracosis 10.0
22 infant gynecomastia 10.0
23 neutropenia 10.0
24 gynecomastia 10.0
25 relapsing-remitting multiple sclerosis 10.0
26 glioblastoma multiforme 10.0
27 thymoma 10.0
28 amelanotic melanoma 10.0
29 infertility 10.0
30 plasma cell neoplasm 10.0
31 lung disease 10.0
32 neuropathy 10.0
33 glioma 10.0
34 asbestos intoxication 10.0
35 glial tumor 10.0
36 virus-associated trichodysplasia spinulosa 10.0
37 avascular necrosis 10.0
38 loeffler endocarditis 10.0 FIP1L1 ETV6
39 myofibroma 10.0 PDGFRB ETV6
40 infantile myofibromatosis 10.0 PDGFRB ETV6
41 myelodysplastic/myeloproliferative neoplasm 10.0 PDGFRB ETV6
42 hypereosinophilic syndrome, idiopathic 10.0 PDGFRB FIP1L1
43 chromosomal triplication 10.0
44 atypical chronic myeloid leukemia 10.0 PDGFRB ETV6
45 endomyocardial fibrosis 10.0 PDGFRB FIP1L1
46 aggressive systemic mastocytosis 9.9 PDGFRB FIP1L1
47 systemic mastocytosis 9.9 PDGFRB FIP1L1
48 mastocytosis 9.8 PDGFRB FIP1L1
49 chronic leukemia 9.8 PDGFRB FIP1L1
50 primary hypereosinophilic syndrome 9.7 PDGFRB FIP1L1 ETV6

Graphical network of the top 20 diseases related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

Diseases related to Myeloproliferative Disorder, Chronic, with Eosinophilia

Symptoms & Phenotypes for Myeloproliferative Disorder, Chronic, with Eosinophilia

Human phenotypes related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

# Description HPO Frequency HPO Source Accession
1 eosinophilia 31 HP:0001880
2 myeloproliferative disorder 31 HP:0005547
3 malignant eosinophil proliferation 31 HP:0006782

Symptoms via clinical synopsis from OMIM:

malignant eosinophil proliferation

Clinical features from OMIM:


GenomeRNAi Phenotypes related to Myeloproliferative Disorder, Chronic, with Eosinophilia according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.55 NIN
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 9.55 ETV6
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 9.55 ETV6
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-69 9.55 NIN
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.55 ETV6
6 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.44 TP53BP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-117 9.44 NIN
8 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.44 NIN
9 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.44 NIN
10 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.44 NIN
11 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.44 TP53BP1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.44 TP53BP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.44 TP53BP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-216 9.44 TP53BP1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-27 9.44 NIN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.44 NIN
17 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.44 NIN TP53BP1
18 Increased HPV18 LCR reporter activity GR00197-A-1 9.43 CNTLN ETV6 NIN
19 Increased HPV18 LCR reporter activity GR00197-A-3 9.43 ETV6
20 Increased HPV18 LCR reporter activity GR00197-A-4 9.43 ETV6
21 Increased HPV18 LCR reporter activity GR00197-A-6 9.43 ETV6

Drugs & Therapeutics for Myeloproliferative Disorder, Chronic, with Eosinophilia

Drugs for Myeloproliferative Disorder, Chronic, with Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Mercaptopurine Approved Phase 3 50-44-2 667490
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Hydroxyurea Approved Phase 3 127-07-1 3657
Daunorubicin Approved Phase 3 20830-81-3 30323
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Thioguanine Approved Phase 3 154-42-7 2723601
Idarubicin Approved Phase 3 58957-92-9 42890
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
Polyestradiol phosphate Approved Phase 3 28014-46-2
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Neurotransmitter Agents Phase 3
20 Excitatory Amino Acid Antagonists Phase 3
21 Anesthetics, Dissociative Phase 3
22 Analgesics Phase 3
23 Cola Phase 3
24 Liver Extracts Phase 3
25 Ophthalmic Solutions Phase 3
26 Keratolytic Agents Phase 3
27 Hydrocortisone 17-butyrate 21-propionate Phase 3
28 Hydrocortisone-17-butyrate Phase 3
29 Hydrocortisone hemisuccinate Phase 3
asparaginase Phase 3
31 Narcotics Phase 3
32 Analgesics, Opioid Phase 3
33 Anesthetics Phase 3
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Estradiol 17 beta-cypionate Phase 3
37 Contraceptives, Oral Phase 3
38 Contraceptive Agents Phase 3
39 Contraceptives, Oral, Combined Phase 3
40 Estradiol 3-benzoate Phase 3
41 Norgestimate, ethinyl estradiol drug combination Phase 3
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
Voriconazole Approved Phase 2 137234-62-9 71616
Adenosine Approved, Investigational Phase 2 58-61-7 60961
Methoxsalen Approved Phase 2 298-81-7 4114
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693 40926

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
5 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
6 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
7 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
8 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
9 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
10 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
11 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
12 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
15 Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
16 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
17 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
18 Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant Completed NCT00530218 Phase 2 Ganciclovir
19 Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial Completed NCT00068276 Phase 2
20 A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes Completed NCT00030550 Phase 2 thalidomide
21 Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS) Completed NCT00022048 Phase 1, Phase 2
22 A Phase II Study on the Effectiveness of Thalomid (Thalidomide) Combined With Procrit (Erythropoietin) for the Treatment of Anemia in Patients With Low and Intermediate Risk-1 (IPSS Score Less Than or Equal to 1.5) Myelodysplastic Syndromes Completed NCT00053001 Phase 2 thalidomide
23 A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers Completed NCT00042822 Phase 2 romidepsin
24 A Phase II Study Of Amifostine In Children With Myelodysplastic Syndrome Completed NCT00098683 Phase 2 amifostine trihydrate
25 A Phase II Study of VNP40101M For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia Completed NCT00083187 Phase 2 hydroxyurea;laromustine
26 Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies Completed NCT00014495 Phase 1, Phase 2 cytarabine
27 A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS) Completed NCT00072475 Phase 2 vatalanib
28 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
29 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
30 Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders Completed NCT00028730 Phase 2 cyclophosphamide;fludarabine phosphate;thiotepa
31 A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies Completed NCT00014469 Phase 2 busulfan;melphalan;methotrexate;tacrolimus
32 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
33 A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes Completed NCT00045305 Phase 2 Cyclosporine;Methotrexate;Photopheresis;Mycofenolate mofetil;Pentostatin
34 Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies Completed NCT00627666 Phase 2 busulfan;fludarabine phosphate;leucovorin calcium;methotrexate
35 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
36 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
37 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
38 Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphohematopoietic Malignancies Completed NCT00027560 Phase 2 cyclosporine;fludarabine phosphate;melphalan
39 A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor Completed NCT00002718 Phase 2 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
40 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
41 Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
42 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
43 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
44 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
45 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
46 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
47 Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Recruiting NCT01787487 Phase 2 Azacitidine;Ruxolitinib Phosphate
48 A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Active, not recruiting NCT03075826 Phase 2 SGI-110
49 Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome Terminated NCT00104806 Phase 2 arsenic trioxide
50 Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation Terminated NCT01118013 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus

Search NIH Clinical Center for Myeloproliferative Disorder, Chronic, with Eosinophilia

Genetic Tests for Myeloproliferative Disorder, Chronic, with Eosinophilia

Genetic tests related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

# Genetic test Affiliating Genes
1 Myeloproliferative Disorder, Chronic, with Eosinophilia 29 PDGFRB

Anatomical Context for Myeloproliferative Disorder, Chronic, with Eosinophilia

MalaCards organs/tissues related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

Bone Marrow, Bone, Myeloid, T Cells, Liver, Nk Cells

Publications for Myeloproliferative Disorder, Chronic, with Eosinophilia

Articles related to Myeloproliferative Disorder, Chronic, with Eosinophilia:

# Title Authors PMID Year
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. 56
12181402 2002
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. 56
8168137 1994
Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association. 56
3478077 1987
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. 61
19394693 2009
Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia. 61
16343267 2006
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. 61
15087377 2004
Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. 61
10741923 2000
Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12) 61
9639434 1998
A myeloproliferative disorder with eosinophilia associated with a unique translocation (3;5). 61
8943895 1996
Translocation t(5;12)(q31-q33;p12-p13): a non-random translocation associated with a myeloid disorder with eosinophilia. 61
7803280 1994

Variations for Myeloproliferative Disorder, Chronic, with Eosinophilia

Expression for Myeloproliferative Disorder, Chronic, with Eosinophilia

Search GEO for disease gene expression data for Myeloproliferative Disorder, Chronic, with Eosinophilia.

Pathways for Myeloproliferative Disorder, Chronic, with Eosinophilia

GO Terms for Myeloproliferative Disorder, Chronic, with Eosinophilia

Cellular components related to Myeloproliferative Disorder, Chronic, with Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 centriole GO:0005814 8.62 NIN CNTLN

Biological processes related to Myeloproliferative Disorder, Chronic, with Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 centriole-centriole cohesion GO:0010457 8.62 NIN CNTLN

Sources for Myeloproliferative Disorder, Chronic, with Eosinophilia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....